Graded review
Fountain Life vs Human Longevity Inc: MRI Clinics Compared
Two whole-body-MRI longevity clinics compared. The headline isn't the price — it's the incidentaloma problem: most scary scan findings turn out to be nothing.
Evidence scorecard
Top of the scorecard
Grade A
CoreAge Rx
Doctor-reviewed longevity peptides and NAD+ with one published per-protocol price and built-in human support.
$93–$99/mo (12-mo plan)
Check availability- Pricing
- Flat monthly, no membership
- Pharmacy
- 503A compounding pharmacy
- Labs
- No labs required
- Consult
- Clinician review included
- Support
- 1:1 nurse + dietitian
Advertising disclosure — we may earn a commission at no extra cost to you. Affiliate partners are listed first on the scorecard.
Also on the scorecard
Grade C
Try Ageless
Every advertised longevity price is an intro-code rate, and the site says outright the real figure arrives after review.
$176–$249/mo list
Visit Try AgelessEvery advertised longevity price is a limited-time intro-code rate: the real list prices are $249 (NAD+ injection) and $176 (sermorelin injection), not the $199 and $126 shown. Compounded and not FDA-approved. Graded on the same rubric as every other provider on our scorecard.
Fountain Life and Human Longevity Inc (HLI) are the two best-known names in a specific, expensive corner of longevity care: the concierge clinic built around a whole-body and brain MRI. Both sell the same core promise — pay five figures, get scanned head-to-toe, and "catch disease early" before it can hurt you. Both anchor that promise to advanced imaging plus genomics, bloodwork, and an in-person physician.
If you're choosing between them, the temptation is to compare price, scanner brand, and amenities. That comparison matters least. The thing that should drive your decision — and that neither clinic's marketing puts front and center — is what happens after the scan finds something. Because in apparently healthy people, whole-body MRI finds "something" remarkably often, and most of the time that something turns out to be nothing. That phenomenon has a name — the incidentaloma — and it is the single most important fact in this entire category. We'll lead with it, then compare the two clinics honestly.
Read this first
The incidentaloma problem
- Whole-body MRI of healthy adults flags potentially serious incidental findings in ~3.9% of scans.
- Of followed-up serious findings, only ~20.5% had a serious final diagnosis — four in five were false alarms.
- Each false alarm can cascade into repeat scans, referrals, biopsies, and anxiety — a documented harm.
- Both clinics sell the same five-figure imaging-and-genomics model; the incidentaloma math is identical for both.
The headline problem: incidentalomas, not the price
When you image an asymptomatic person from head to pelvis, you find incidental abnormalities — spots, nodules, cysts, lesions — that were never causing symptoms and may never have. A systematic review and meta-analysis of brain and body MRI in apparently asymptomatic adults found that potentially serious incidental findings turned up in roughly 3.9% of whole brain-and-body scans, with suspected malignancies in a fraction of a percent per region1. That sounds low until you remember these clinics scan thousands of healthy people — and that the same review found that, of the potentially serious findings that were followed up, only about one in five (20.5%) had a serious final diagnosis1. The other four in five were false alarms that still triggered worry, repeat imaging, specialist visits, and sometimes biopsies.
Zoom out to imaging in general and the picture gets starker. An umbrella review of incidental findings across imaging types found prevalence ranging from under 5% on some scans to more than a third of images on cardiac MRI, chest CT, and CT colonography — and that when those incidental findings were worked up, the share that proved malignant was often modest (under 5% for brain, parotid, and adrenal findings, for example)2. Whole-body MRI specifically, even in carefully screened healthy research volunteers, routinely surfaces incidental findings in a large minority of participants3. Intracranial incidental findings alone show up on a meaningful fraction of brain MRIs in the general population4.
This is not a knock on MRI as a technology. It is a statement about what screening asymptomatic people does: the lower your pre-test probability of disease, the more likely a positive finding is a false alarm. That is just how predictive values work, and it is why population imaging programs — like the German National Cohort, which scanned tens of thousands of people by whole-body MRI — had to build entire protocols around how to handle and communicate incidental findings, not just how to acquire images56.
Strength of evidence
- AWB-MRI of healthy people → frequent incidental findingsStrong evidence
Systematic reviews + large population cohorts confirm high incidental-finding rates.
- AMany findings → false alarm / overdiagnosisStrong evidence
Only ~20% of serious-looking findings proved serious; thyroid/adrenal overdiagnosis well documented.
- DWB-MRI screening → longer lifespanInsufficient
No completed RCT shows a survival benefit from screening asymptomatic people.
Why "early detection" can become overdiagnosis
The marketing logic is intuitive: find disease early, treat it early, live longer. The hidden flaw is overdiagnosis — detecting "disease" that would never have caused symptoms or death in your lifetime, then treating it anyway and incurring the harms of treatment with none of the benefit. Thyroid cancer is the textbook case: a wave of incidental thyroid nodules detected on imaging drove a surge in thyroid-cancer diagnoses without a matching rise in deaths, because many of those cancers were indolent and would never have mattered7. Adrenal "incidentalomas" tell a similar story — most are benign, non-functioning, and clinically irrelevant, yet each one detected starts a cascade of hormonal workups and repeat scans8.
Even formal, evidence-graded screening programs wrestle with this. The US Preventive Services Task Force's prostate-cancer screening guidance is built explicitly around the trade-off that PSA-based detection finds many cancers that would never have harmed the man, at the cost of biopsies and treatments that do harm9. That's a single, well-studied test in a defined-risk population. A whole-body MRI in a healthy 45-year-old casts a vastly wider net — and the wider the net, the more false alarms and indolent findings you haul in. The downstream "cascade of care" — the follow-up scans, referrals, biopsies, anxiety, and occasional procedural complications set off by a single incidental finding — is a documented harm, not a hypothetical one6.
None of this means whole-body MRI never helps anyone. It occasionally catches a genuinely serious, actionable problem early, and for some individuals that matters enormously. The honest framing is one of base rates: across thousands of healthy people scanned, the program will catch a small number of real, treatable problems and generate a much larger number of false alarms and overdiagnoses. Whether that trade is worth $20,000 a year is a value judgment — but you can only make it if the clinic tells you both sides. Most of the marketing tells you only the first.
Fountain Life vs HLI: how they actually compare
With that frame in place, here's how the two clinics line up. Both are concierge diagnostic programs centered on advanced imaging; the differences are in emphasis, structure, and price — none of which changes the incidentaloma math above.
At a glance
| Fountain Life | Human Longevity Inc | |
|---|---|---|
| Core scan | Full-body + brain MRI, coronary CT | Whole-body + brain MRI (Health Nucleus) |
| Emphasis | Annual membership experience, more locations | Whole-genome sequencing heritage |
| Structure | APEX / CORE annual membership tiers | Flagship assessment + follow-on |
| Reported price | ~$19,500/yr flagship (not published) | ~$25,000 assessment (not published) |
| Lifespan-extension RCT | None published | None published |
Fountain Life markets an annual membership (its APEX and CORE tiers) built around a full-body and brain MRI, AI-assisted image reading, coronary CT angiography, advanced bloodwork, and genomics, with care coordination throughout the year. Pricing is not published on its site — you're directed to book a call — but its flagship membership has been widely reported in the roughly $19,500-per-year range, with lower-cost assessment tiers. Treat any figure as approximate and confirm directly; concierge longevity pricing changes often and varies by location and package. We put the program through the same five-factor rubric as every other provider on the board — where the unpublished pricing is itself part of the score.
Human Longevity Inc pioneered this model with its Health Nucleus, the San Diego clinic that paired whole-body and brain MRI with whole-genome sequencing and deep phenotyping. HLI leaned heaviest on the genomics side — it was founded by genomics figures and built around sequencing-plus-imaging "data on you." Its flagship assessment has historically been reported in the ~$25,000 range, again not transparently posted and subject to change.
The practical upshot: these are more alike than different. Both are five-figure, imaging-and-genomics concierge programs aimed at affluent, mostly asymptomatic people who want a deep data snapshot. If what appeals to you is the in-person, clinician-supervised part rather than the MRI, the cheaper analogue is a clinic membership rather than a concierge tier — tiered monthly plans with the IV drips and functional labs billed per session buy a fraction of the diagnostics for a fraction of the money, and the evidence behind those drips is thinner than the imaging. HLI tilts toward genomics heritage; Fountain Life tilts toward a productized annual-membership experience with more locations. Neither has published evidence from a completed randomized trial showing its program extends lifespan — which is true of the entire longevity-clinic category, not a unique failing of either. We put that field-wide caveat in context in longevity medicine: what's proven vs hyped and weigh whether any concierge clinic earns its price in are longevity clinics worth it?.
What to ask before you pay either one
If you're seriously considering one of these programs, the smart questions aren't about scanner resolution. They're about what happens when the scan lights up:
- What's your incidental-finding rate, and what share turn out to be nothing? A clinic that scans healthy people should know its own false-alarm and overdiagnosis numbers. If it can't or won't tell you, that's a signal.
- Who pays for the downstream workup? The MRI is the cheap part. The biopsies, repeat scans, and specialist referrals an incidental finding triggers are usually not in the membership — and not always covered by insurance, since they stem from an out-of-network screening test.
- How do you counsel patients against overtreatment? A responsible program actively talks people out of chasing indolent findings, not just into more testing.
- Is the genomics actionable or just interesting? Whole-genome data generates a lot of "variants of uncertain significance" that change nothing about your care.
For most people, the rational alternative is a good primary-care relationship plus the standard, evidence-graded screenings appropriate to their age and risk — colonoscopy, age-appropriate mammography, lung-cancer CT for actual smokers, blood pressure, lipids, A1c — which have been vetted for exactly the benefit-versus-overdiagnosis balance these whole-body programs skip. We map the cheaper, more evidence-aligned tiers in how much does a longevity clinic cost? and contrast the program structures in concierge vs membership longevity programs. And if you do want a graded shortlist of programs by oversight and value, we rank them in our guide to the best longevity clinics.
The bottom line
Fountain Life vs HLI is the wrong first question. Both are credible, well-built concierge clinics selling essentially the same five-figure imaging-and-genomics product; HLI leans genomics, Fountain Life leans membership experience, and the price gap is smaller than the marketing gap. The right first question is whether whole-body MRI screening of a healthy person is a good idea at all — and the evidence says the answer is "sometimes, with eyes open." These scans reliably find incidental abnormalities, most of which are false alarms or overdiagnosed non-threats, and the resulting cascade of follow-up testing is a real harm with real costs126. If you go in understanding that — and you can afford the downstream workups the scan may set in motion — either clinic can deliver a deep data snapshot. Just don't mistake "they found something" for "they saved your life." Far more often, the most valuable result a whole-body MRI can give a healthy person is a clean one.
Frequently asked questions
Is Fountain Life or Human Longevity Inc better?
They are more alike than different — both are five-figure concierge clinics built around a whole-body and brain MRI plus advanced bloodwork and genomics. Human Longevity Inc leans on its whole-genome-sequencing heritage; Fountain Life leans on a productized annual membership with more locations. Neither has published evidence from a completed randomized trial showing its program extends lifespan, so the choice is mostly about structure, location, and price — not proven outcomes.
What is an incidentaloma?
An incidentaloma is an abnormality found by chance on imaging — a spot, nodule, or lesion that wasn't causing symptoms and may never have. Whole-body MRI of healthy people finds them often: a systematic review found potentially serious incidental findings in about 3.9% of brain-and-body scans, and only about one in five followed-up serious findings turned out to be genuinely serious. The rest are false alarms that can trigger more scans, referrals, and biopsies.
Can a whole-body MRI actually extend my life?
There is no completed randomized trial showing that whole-body MRI screening of asymptomatic people extends lifespan. It can occasionally catch a serious, treatable problem early, but in healthy people it far more often produces false alarms and overdiagnosed findings that lead to unnecessary testing. The most valuable result for a healthy person is usually a clean one.
How much do Fountain Life and Human Longevity Inc cost?
Neither publishes pricing openly. Fountain Life's flagship annual membership has been reported around $19,500 per year, with lower-cost assessment tiers; Human Longevity Inc's flagship Health Nucleus assessment has historically been reported around $25,000. Treat both as approximate and confirm directly, and remember the downstream workups an incidental finding triggers are usually not included.
References
- Gibson LM, Paul L, Chappell FM, et al. (2018). Potentially serious incidental findings on brain and body magnetic resonance imaging of apparently asymptomatic adults: systematic review and meta-analysis.. BMJ. https://pubmed.ncbi.nlm.nih.gov/30467245/
- O'Sullivan JW, Muntinga T, Grigg S, Ioannidis JPA (2018). Prevalence and outcomes of incidental imaging findings: umbrella review.. BMJ. https://pubmed.ncbi.nlm.nih.gov/29914908/
- Morin SH, Cobbold JF, Lim AK, et al. (2009). Incidental findings in healthy control research subjects using whole-body MRI.. European Journal of Radiology. https://pubmed.ncbi.nlm.nih.gov/18818038/
- Sunny DE, Amoo M, Al Breiki M, et al. (2022). Prevalence of incidental intracranial findings on magnetic resonance imaging: a systematic review and meta-analysis.. Acta Neurochirurgica. https://pubmed.ncbi.nlm.nih.gov/35525892/
- Bamberg F, Kauczor HU, Weckbach S, et al. (2015). Whole-Body MR Imaging in the German National Cohort: Rationale, Design, and Technical Background.. Radiology. https://pubmed.ncbi.nlm.nih.gov/25989618/
- Gibson LM, Littlejohns TJ, Adamska L, et al. (2018). Impact of detecting potentially serious incidental findings during multi-modal imaging.. Wellcome Open Research. https://pubmed.ncbi.nlm.nih.gov/30009267/
- Hoang JK, Nguyen XV, Davies L (2015). Overdiagnosis of Thyroid Cancer: Answers to Five Key Questions.. Academic Radiology. https://pubmed.ncbi.nlm.nih.gov/26100186/
- Kastelan D, Dusek T (2015). The clinical course of patients with adrenal incidentaloma: is it time to reconsider the current recommendations?. European Journal of Endocrinology. https://pubmed.ncbi.nlm.nih.gov/26024670/
- Grossman DC, Curry SJ, Owens DK, et al. (US Preventive Services Task Force) (2018). Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.. JAMA. https://pubmed.ncbi.nlm.nih.gov/29801017/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
More graded reviews
Longevity Medicine: What's Proven vs Hyped
An honest, evidence-graded tour of the longevity toolkit — what has human outcome RCTs versus what is animal or mechanistic-only.
ReadDo NAD+ and Peptides Actually Extend Lifespan?
NAD+ precursors reliably raise NAD+ but show modest, mixed human outcomes. Peptides and growth hormone carry real cautions. An honest evidence review.
ReadRapamycin & Metformin for Longevity: The Evidence
Strong animal data, a glaring human RCT gap. What the PEARL pilot, the TAME rationale, and metformin's observational signal really show.
ReadAre Longevity Clinics Worth It?
DTC and IV longevity clinics sit on the weakest evidence in the field. What a critical review found, and how to vet a provider before paying.
ReadRapamycin for Longevity: Hype vs Evidence
Rapamycin is the most reproducible lifespan extender in mice — but there is no human longevity trial. An honest split of the hype from the evidence.
ReadLongevity Clinics vs Lab Memberships vs Rx Telehealth: What Each Delivers
The longevity market splits into four bands: concierge clinics, membership programs, DTC labs, single-product Rx. What each delivers, and who it's for.
Read